{"id":917172,"date":"2025-12-08T08:32:33","date_gmt":"2025-12-08T13:32:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/"},"modified":"2025-12-08T08:32:33","modified_gmt":"2025-12-08T13:32:33","slug":"agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/","title":{"rendered":"Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CAMBRIDGE, Mass., Dec.  08, 2025  (GLOBE NEWSWIRE) &#8212; Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on the supplemental New Drug Application (sNDA) for mitapivat for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia and that the sNDA remains under active review. The Prescription Drug User Fee Act (PDUFA) goal date issued by the FDA was December 7, 2025.<\/p>\n<p>Agios is collaborating closely with the FDA to finalize the labeling documents and Risk Evaluation and Mitigation Strategy (REMS) materials. The FDA has not requested, and the company has not submitted, any new or additional efficacy or safety data.<\/p>\n<p>The FDA has not provided a timeline for its regulatory decision. Agios continues to work expeditiously with the FDA to conclude the review of the sNDA.<\/p>\n<p>\n        <strong>About Agios: Fueled by Connections to Transform Rare Diseases\u2122 <\/strong><br \/>\n        <br \/>At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities \u2013 collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=R078iUKwLbcNyE598xDzlQwYqb2ptkcq5-n_rm_YT5kFWBcWpISUjfziBcRUKMpbWg7W0taUS1L5FazamVgMAg==\" rel=\"nofollow\" target=\"_blank\">www.agios.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aEv5tNM-Mqu475EzEgCmpZCgsIxDBpHHX9ik4OuXt1am5i_HuRNhNkyhT9FnyRjRJIq5sVK-44FZxCUo9MGRHC13zztp8GFGRvLQyv1MkeE=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BJAiOzXWYer_RdJiZkgELABGn30bNrGp5UOFYgoarcJWRJRWQyaPjcvDxPPMQky8swuBYe6a-wBmOgMnIcvxOQ==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of Agios\u2019 products, including mitapivat, its interactions with regulators, including the FDA, and its strategic plans and focus. The words \u201canticipate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201chope,\u201d \u201cmilestone,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpossible,\u201d \u201cstrategy,\u201d \u201cwill,\u201d \u201cvision,\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios\u2019 current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios\u2019 product candidates will successfully continue. There can be no guarantee that any positive developments in Agios\u2019 business will result in stock price appreciation. Management&#8217;s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation: the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios\u2019 results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; risks and uncertainties related to the impact of pandemics or other public health emergencies to Agios\u2019 business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios\u2019 ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios&#8217; ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios\u2019 ability to establish and maintain key collaborations; uncertainty regarding any royalty payments related to the sale of its oncology business or any milestone or royalty payments related to its in-licensing of AG-236, and the uncertainty of the timing of any such payments; uncertainty of the results and effectiveness of the use of Agios\u2019 cash and cash equivalents; and general economic and market conditions. These and other risks are described in greater detail under the caption &#8220;Risk Factors&#8221; included in Agios\u2019 public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.\u00a0<\/p>\n<p>\n        <strong>Contacts:<\/strong><\/p>\n<p>        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Morgan Sanford, Vice President, Investor Relations <br \/>Agios Pharmaceuticals<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xqpXM4hyKoQyQvgDEMjeFoflEjJLT_XqSIRFnb1gjwhXw1Fs0WyBmUZ5HfFS4Uq27yR1_tKfGrvFwvu8AskrPMl98x43EJuJHhFBu-yb9sUwGiSAk8Dj-2a4lXTi8ARl\" rel=\"nofollow\" target=\"_blank\"><u>morgan.sanford@agios.com<\/u><\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Eamonn Nolan, Senior Director, Corporate Communications<br \/>Agios Pharmaceuticals<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=73JcZFQ6OerWqZkxg1sdQzCKA3nyqAcLAvA2keoC_XAF21on1E_eNAMRbDVVIxBZewH778CNATI79WSux7_5oiu50RoCM-yvS2HQcTRN27c=\" rel=\"nofollow\" target=\"_blank\"><u>eamonn.nolan@agios.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODIxNiM3MzEwMTg2IzIwMDgyMTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YmE2ZDY3Y2EtNGI1OC00NjYyLTkzYmUtZTNiMmNhNzcwZTY1LTEwMTk3OTEtMjAyNS0xMi0wOC1lbg==\/tiny\/Agios-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) &#8212; Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on the supplemental New Drug Application (sNDA) for mitapivat for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia and that the sNDA remains under active review. The Prescription Drug User Fee Act (PDUFA) goal date issued by the FDA was December 7, 2025. Agios is collaborating closely with the FDA to finalize the labeling documents and Risk Evaluation and Mitigation Strategy (REMS) materials. The FDA has not requested, and the company has &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-917172","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) &#8212; Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on the supplemental New Drug Application (sNDA) for mitapivat for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia and that the sNDA remains under active review. The Prescription Drug User Fee Act (PDUFA) goal date issued by the FDA was December 7, 2025. Agios is collaborating closely with the FDA to finalize the labeling documents and Risk Evaluation and Mitigation Strategy (REMS) materials. The FDA has not requested, and the company has &hellip; Continue reading &quot;Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T13:32:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODIxNiM3MzEwMTg2IzIwMDgyMTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia\",\"datePublished\":\"2025-12-08T13:32:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\\\/\"},\"wordCount\":775,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODIxNiM3MzEwMTg2IzIwMDgyMTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\\\/\",\"name\":\"Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODIxNiM3MzEwMTg2IzIwMDgyMTg=\",\"datePublished\":\"2025-12-08T13:32:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODIxNiM3MzEwMTg2IzIwMDgyMTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODIxNiM3MzEwMTg2IzIwMDgyMTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/","og_locale":"en_US","og_type":"article","og_title":"Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) &#8212; Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on the supplemental New Drug Application (sNDA) for mitapivat for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia and that the sNDA remains under active review. The Prescription Drug User Fee Act (PDUFA) goal date issued by the FDA was December 7, 2025. Agios is collaborating closely with the FDA to finalize the labeling documents and Risk Evaluation and Mitigation Strategy (REMS) materials. The FDA has not requested, and the company has &hellip; Continue reading \"Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-08T13:32:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODIxNiM3MzEwMTg2IzIwMDgyMTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia","datePublished":"2025-12-08T13:32:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/"},"wordCount":775,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODIxNiM3MzEwMTg2IzIwMDgyMTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/","name":"Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODIxNiM3MzEwMTg2IzIwMDgyMTg=","datePublished":"2025-12-08T13:32:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODIxNiM3MzEwMTg2IzIwMDgyMTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODIxNiM3MzEwMTg2IzIwMDgyMTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agios-provides-update-on-u-s-snda-for-mitapivat-in-thalassemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=917172"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917172\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=917172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=917172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=917172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}